Literature DB >> 15056213

An in vitro dual model of mycobacterial granulomas to investigate the molecular interactions between mycobacteria and human host cells.

Marie-Pierre Puissegur1, Catherine Botanch, Jean-Luc Duteyrat, Georges Delsol, Claude Caratero, Frédéric Altare.   

Abstract

In the majority of individuals infected with Mycobacterium tuberculosis, the bacilli cause a long-term asymptomatic infection called latent tuberculosis, a state during which the bacilli reside within granulomas. Latently infected individuals have around 10% risk of progression to clinical disease at a later stage. Determining the state of the mycobacteria and the host cells during this latent phase, i.e. within the granulomas, would greatly improve our understanding of the physiopathology of tuberculosis, and thus enable the development of new therapeutic means to treat the one-third of the world's population who are latently infected. We have developed an in vitro model of human mycobacterial granulomas, enabling the cellular and molecular analysis of the very first steps in the host granulomatous response to either mycobacterial compounds or live mycobacterial species. In vitro mycobacterial granulomas mimic natural granulomas very well, with the progressive recruitment of macrophages around live bacilli or mycobacterial antigen-coated beads, their differentiation into multinucleated giant cells and epithelioid cells, and the final recruitment of a ring of activated lymphocytes. Besides morphological similarities, in vitro granulomas also functionally resemble natural ones, with the development of intense cellular co-operation and intracellular mycobactericidal activities.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15056213     DOI: 10.1111/j.1462-5822.2004.00371.x

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  68 in total

Review 1.  Unfolding the relationship between secreted molecular chaperones and macrophage activation states.

Authors:  Brian Henderson; Samantha Henderson
Journal:  Cell Stress Chaperones       Date:  2008-10-29       Impact factor: 3.667

2.  Mycolates of Mycobacterium tuberculosis modulate the flow of cholesterol for bacillary proliferation in murine macrophages.

Authors:  Ilke Vermeulen; Mark Baird; Juma Al-Dulayymi; Muriel Smet; Jan Verschoor; Johan Grooten
Journal:  J Lipid Res       Date:  2017-02-13       Impact factor: 5.922

Review 3.  Killing Mycobacterium tuberculosis In Vitro: What Model Systems Can Teach Us.

Authors:  Tracy L Keiser; Georgiana E Purdy
Journal:  Microbiol Spectr       Date:  2017-06

Review 4.  In Vitro Granuloma Models of Tuberculosis: Potential and Challenges.

Authors:  Paul Elkington; Maria Lerm; Nidhi Kapoor; Robert Mahon; Elsje Pienaar; Dongeun Huh; Deepak Kaushal; Larry S Schlesinger
Journal:  J Infect Dis       Date:  2019-05-24       Impact factor: 5.226

5.  The Mycobacterium tuberculosis MmpL11 Cell Wall Lipid Transporter Is Important for Biofilm Formation, Intracellular Growth, and Nonreplicating Persistence.

Authors:  Catherine C Wright; Fong Fu Hsu; Eusondia Arnett; Jennifer L Dunaj; Patrick M Davidson; Sophia A Pacheco; Melanie J Harriff; David M Lewinsohn; Larry S Schlesinger; Georgiana E Purdy
Journal:  Infect Immun       Date:  2017-07-19       Impact factor: 3.441

6.  High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis.

Authors:  Mayra Silva-Miranda; Euloge Ekaza; Adrien Breiman; Karim Asehnoune; David Barros-Aguirre; Kevin Pethe; Fanny Ewann; Priscille Brodin; Lluís Ballell-Pages; Frédéric Altare
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

7.  FoxP3+ regulatory T cells suppress early stages of granuloma formation but have little impact on sarcoidosis lesions.

Authors:  Cécile Taflin; Makoto Miyara; Dominique Nochy; Dominique Valeyre; Jean-Marc Naccache; Frédéric Altare; Pascale Salek-Peyron; Cécile Badoual; Patrick Bruneval; Julien Haroche; Alexis Mathian; Zahir Amoura; Gary Hill; Guy Gorochov
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

Review 8.  The present state of the tuberculosis drug development pipeline.

Authors:  M Daben J Libardo; Helena Im Boshoff; Clifton E Barry
Journal:  Curr Opin Pharmacol       Date:  2018-08-23       Impact factor: 5.547

9.  Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism.

Authors:  Mi-Jeong Kim; Helen C Wainwright; Michael Locketz; Linda-Gail Bekker; Gabriele B Walther; Corneli Dittrich; Annalie Visser; Wei Wang; Fong-Fu Hsu; Ursula Wiehart; Liana Tsenova; Gilla Kaplan; David G Russell
Journal:  EMBO Mol Med       Date:  2010-07       Impact factor: 12.137

10.  High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors.

Authors:  Thierry Christophe; Mary Jackson; Hee Kyoung Jeon; Denis Fenistein; Monica Contreras-Dominguez; Jaeseung Kim; Auguste Genovesio; Jean-Philippe Carralot; Fanny Ewann; Eun Hye Kim; Sae Yeon Lee; Sunhee Kang; Min Jung Seo; Eun Jung Park; Henrieta Skovierová; Ha Pham; Giovanna Riccardi; Ji Youn Nam; Laurent Marsollier; Marie Kempf; Marie-Laure Joly-Guillou; Taegwon Oh; Won Kyung Shin; Zaesung No; Ulf Nehrbass; Roland Brosch; Stewart T Cole; Priscille Brodin
Journal:  PLoS Pathog       Date:  2009-10-30       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.